



PH: 775-453-0667 | Fax: 775-470-8478

## **Briumvi Order Form**

Patient Na	me:			DOB:	
Phone:		Address:			
				Allergies:	
DIAGNOS	IS:				
☐ Mu	ıltiple Sclerosis ICD-10: G3	5			
Тур	oe: 🗖 Relapsing-Remittin	g 🖵 Primary-Pr	ogressive 📮	Secondary-Progressive	:ed
☐ Oth	ner	ICD-10:		<u></u>	
ORDER FO	OR BRIUMVI (UBLITUXIN	ЛАВ-XIIY):			
		_		wed by $450~\text{mg}$ IV $2~\text{weeks}$ later, and then $4~\text{cm}$	50 mg IV
eve	ery 24 weeks starting 24 w	eeks after the ini	itial dose x 1 y	vear	
☐ Ma	intenance Dose: 450 mg I	V every 24 week	s starting 24 v	veeks after the initial dose x 1 year	
**Patient	will be monitored for at le	east 1 hour follow	wing the com	pletion of the first 2 infusions**	
PRE-MEDI	CATIONS:				
	☑ Acetaminophen 650m	ng PO			
	☑ Diphenhydramine 25r	ng PO or IV or Zy	yrtec 10 mg P	0	
	☑ Hydrocortisone 100m	g IV or Methylpr	ednisolone 12	25mg IV	
	☐ Additional Pre-Medica	ations:			
MAY ADM	INISTER IF NEEDED FOR A	LLERGIC REACTION	ON:		
✓ Ne	vada Infusion Hypersensit	civity Reaction O	rder Set		
☐ Oth	ner:				
ACCESS: Pe	eripheral IV, Port, Midline,	or PICC line			
	: 10 mls NS pre/post infus		5ml for port –	· 100 units/ml	
	Per Nevada Infusion			,	
LABS ORDI	ERS:		Fa	ax results to:	
PROVIDER	INFORMATION:				
	Name:			NPI:	
Physician S	Signature:			Date:	
Point of Co	ontact·	Pho	one.	Fmail·	





Patient Name: \_\_\_\_\_ DOB:\_\_\_\_\_

Please Include Required Documentation for Expedited Order Processing & Insurance Approval:
☐ Signed provider orders (page 1)
☐ Patient demographic and insurance information
☐ Patient's current medication list
☐ Supporting recent clinical notes and H&P (to support primary diagnosis)
$\square$ Supporting documentation to include past tried and/or failed therapies
$\square$ Supporting clinical notes to include any past tried and/or failed therapies, intolerance, benefits, or
contraindications to conventional therapy
☐ Other medical necessity documentation (please include):